Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd Ordinary Shares (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
UroGen Pharma's Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie...

URGN : 52.42 (-4.38%)
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast Limited (NASDAQ:MESO),...

MESO : 5.86 (-3.30%)
URGN : 52.42 (-4.38%)
CSGP : 412.09 (-0.72%)
TTGT : 29.14 (+1.08%)
ANCX : 30.19 (+0.40%)
SINA : 88.81 (+0.92%)
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix, UroGen's Chief...

URGN : 52.42 (-4.38%)
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron...

URGN : 52.42 (-4.38%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 52.42 (-4.38%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 52.42 (-4.38%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 52.42 (-4.38%)
ACIA : 33.33 (+0.39%)
TCPC : 14.40 (-0.21%)
DORM : 72.23 (+0.65%)
ACGL : 26.48 (+0.46%)
CONE : 57.85 (-0.31%)
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis

NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis...

URGN : 52.42 (-4.38%)
NVS : 75.06 (+1.46%)
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data...

URGN : 52.42 (-4.38%)
Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Prothena Corporation PLC (NASDAQ:PRTA),...

WLTW : 154.16 (+1.15%)
FLWS : 12.90 (-0.77%)
URGN : 52.42 (-4.38%)
FBNK : 31.30 (-0.79%)
PRTA : 15.67 (+4.19%)
MFG : 3.40 (+0.89%)
UroGen Reports Fourth Quarter and Full Year 2017 Financial Results

Presentation of MitoGel(TM) Interim Analysis from OLYMPUS Pivotal Trial in Patients with Low Grade Upper Tract Urothelial Cancer Planned at Upcoming Medical Meeting

URGN : 52.42 (-4.38%)
UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 52.42 (-4.38%)
UroGen to Present at March 2018 Investor Conferences

UroGen Pharma Ltd. (NASDAQ:URGN) today announced that management plans to present at two investor conferences in March 2018:

URGN : 52.42 (-4.38%)
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment...

URGN : 52.42 (-4.38%)
Investment Opportunities in Advanced Bioengineered Drug Delivery

NetworkNewsWire Editorial Coverage

VRX.TO : 32.19 (-2.04%)
PREV.CN : 0.080 (unch)
URGN : 52.42 (-4.38%)
JNJ : 122.84 (+1.14%)
GWPH : 151.25 (+0.16%)
PRVCF : 0.0570 (+3.45%)
VRX : 24.27 (-1.82%)
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing...

URGN : 52.42 (-4.38%)
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the pricing...

URGN : 52.42 (-4.38%)
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer

Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations

URGN : 52.42 (-4.38%)
KITE : 179.99 (+0.11%)
UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron...

URGN : 52.42 (-4.38%)
JPM : 105.75 (-1.64%)
The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

The Zacks Analyst Blog Highlights: AnaptysBio, , Roku, SMART Global Holdings, UroGen Pharma and Calyxt

ANAB : 74.91 (+4.70%)
ROKU : 44.71 (-1.45%)
URGN : 52.42 (-4.38%)
SGH : 35.06 (-12.02%)
CLXT : 20.38 (-1.16%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC -2.19 , FTNT -0.81 , CAKE -2.16 , PLT -0.20 , AEO -0.88
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed Friday steady to fractionally mixed, as July was down 1.11% on the week. The USDA reported a private export sale of 131,300 MT of corn to Mexico this morning. The sale was broke down to 30,000 MT for delivery in 2017/18, with the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar